Prevalence of Psychiatric Disorder in a Methadone Maintenance Population

Callaly, Tom; Trauer, Tom; Munro, Leigh; Whelan, Greg

doi:10.1080/0004867010060507

Cited by 100 publications

(55 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The sharing of knowledge among drug treatment clients and people with hepatitis C about the experience of hepatitis C treatment means that drug treatment clients can be suspicious of the therapies on offer, including current forms such as pegylated interferon. In particular, the high prevalence of mental health problems among drug treatment populations [25][26][27] adds to the concerns of those who might consider treatment, when there is a common perception and substantive evidence that depressive symptoms may be aggravated by interferon treatment for hepatitis C. 23,24 We have attempted to portray the everyday complexity of the lived experience of hepatitis C for drug treatment users and the implications of this complexity for decisions about hepatitis C treatment. Two other "everyday" issues may be relevant to decisions about hepatitis C treatment: competing priorities and discrimination.…”

Section: Discussionmentioning

confidence: 99%

“…The association of interferon-based treatment and major psychiatric side effects is well documented 23,24 as is the high prevalence of mental health problems among drug treatment populations, [25][26][27] echoing accounts such as Alan' s (quoted earlier). The threat of additional mental health problems was a source of concern for participants already coping with anxiety or depression.…”

Section: Planning and Developmentmentioning

confidence: 99%

See 1 more Smart Citation

Drug treatment clients' readiness for hepatitis C treatment: implications for expanding treatment services in drug and alcohol settings

Treloar¹,

Holt²

2008

Aust. Health Review

View full text Add to dashboard Cite

This study explores the perception of and readiness for hepatitis C treatment within a sample of 77 clients already participating in drug treatment, with a view to identifying likely barriers and incentives to hepatitis C treatment within a drug treatment population. Participants with hepatitis C did not demonstrate a consistent, indepth knowledge of the infection, lacked confidence in symptom recognition, and had little awareness of treatment options. Those without obvious symptoms or liver deterioration did not have a pressing interest in treatment, and many had heard concerning stories about the side effects of hepatitis C treatment. For those coping with anxiety or depression, the increased risk of a depressive episode under interferon treatAust Health Rev 2008: 32(3): 570-576 ment was a major barrier to treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Planning and Developmentmentioning

confidence: 99%

Drug treatment clients' readiness for hepatitis C treatment: implications for expanding treatment services in drug and alcohol settings

Treloar¹,

Holt²

2008

Aust. Health Review

View full text Add to dashboard Cite

show abstract

“…The importance of dual diagnoses (psychiatric diagnosis linked to substance abuse) has been well described. The percentage of dual diagnoses ranges from 47 to 76% [32,37] . In an MMT patient population, the prescriptions of benzodiazepines and psychoactive medications cited above already suggest a high prevalence of psychiatric comorbidity and correlate with the evaluation of mental health reported by the practitioners.…”

Section: Discussionmentioning

confidence: 99%

Methadone Maintenance Treatment in the Swiss Canton of Vaud: Demographic and Clinical Data on 1,782 Ambulatory Patients

Pelet¹,

Doll²,

Huissoud³

et al. 2005

Eur Addict Res

View full text Add to dashboard Cite

Using data from the Public Health Service, we studied the demographic and clinical characteristics of 1,782 patients enrolled in methadone maintenance treatment (MMT) during 2001 in the Swiss Canton of Vaud, comparing our findings with the results of a previous study from 1976 to 1986. In 2001, most patients (76.9%) were treated in general practice. Mortality is low in this MMT population (1%/year). While patient age and sex profiles were similar to those found in the earlier study, we did observe a substantial increase in the number of patients and the number of practitioners treating MMT patients, probably reflecting the low-threshold governmental policies and the creation of specialized centers. In conclusion, easier access to MMT enhances the number of patients, but new concerns about the quality of management emerge: benzodiazepine as a concomitant prescription; low rates of screening for hepatitis B, C and HIV, and social and psychiatric preoccupations.

show abstract

“…An apparently stronger association has been detected between SUD and other psychiatric disorders in opioid-dependent populations, in which approximately 70% of subjects meet the criteria for at least one lifetime DSM Axis I (nonsubstance use) disorder and 50% for Axis II personality disorders [4] . Moreover, with regard to the clinical population, the figures obtained are even higher, with rates of psychiatric comorbidity reaching 80-90% for Axis I dis-orders [5][6][7] . Finally, moving from a diagnostic to a subdiagnostic level, a further rise in psychiatric comorbidity is expected, as shown by research studies performed on affective conditions belonging to the 'soft' bipolar spectrum [8] .…”

Section: Introductionmentioning

confidence: 99%

Effect of Psychiatric Severity on the Outcome of Methadone Maintenance Treatment

et al. 2010

View full text Add to dashboard Cite

While psychiatric comorbidity has been shown to produce a negative impact on the outcome of opioid use disorders, longitudinal studies carried out in the context of methadone maintenance treatment programs (MMTP) to evaluate outcomes strictly linked to methadone efficacy have not demonstrated a similar negative influence. To verify whether results obtained considering psychopathology in terms of formal psychiatric diagnoses were replicated when assessing psychopathology in terms of global psychiatric severity, a retrospective cohort study was designed. 259 patients commencing methadone maintenance treatment were divided into two groups on the basis of SCL-90 severity score and compared for retention in treatment, toxicological urine test results and psychological/psychiatric status throughout a one year period of observation. The results of the study suggest that patients in MMTP with high psychiatric severity are not characterized by a lower retention in treatment or higher substance use than those with low psychiatric severity. Moreover, during treatment high severe psychiatric patient status appears to improve significantly for all psychological/psychiatric dimensions explored by SCL-90. These results are consistent with those obtained in previous studies on the efficacy of MMTP, comprehensive of psychiatric care, irrespective of the severity of psychopathology exhibited by patients at the beginning of treatment.

show abstract

Prevalence of Psychiatric Disorder in a Methadone Maintenance Population

Cited by 100 publications

References 21 publications

Drug treatment clients' readiness for hepatitis C treatment: implications for expanding treatment services in drug and alcohol settings

Drug treatment clients' readiness for hepatitis C treatment: implications for expanding treatment services in drug and alcohol settings

Methadone Maintenance Treatment in the Swiss Canton of Vaud: Demographic and Clinical Data on 1,782 Ambulatory Patients

Effect of Psychiatric Severity on the Outcome of Methadone Maintenance Treatment

Contact Info

Product

Resources

About